SLAMF1-derived peptide exhibits cardio protection after permanent left anterior descending artery ligation in mice.
P7
SLAMF1
TLR4
inflammation
myocardial infarction
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
07
02
2024
accepted:
25
03
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
epublish
Résumé
Acute myocardial infarction (MI) results in tissue damage to affected areas of the myocardium. The initial inflammatory response is the most damaging for residual cardiac function, while at later stages inflammation is a prerequisite for proper healing and scar formation. Balancing the extent and duration of inflammation during various stages after MI is thus pivotal for preserving cardiac function. Recently, a signaling lymphocytic activation molecule 1 (SLAMF1)-derived peptide (P7) was shown to reduce the secretion of inflammatory cytokines and protected against acute lipopolysaccharide-induced death in mice. In the present study, we experimentally induced MI by permanent ligation of the left anterior descending artery (LAD) in mice and explored the beneficial effect of immediately administering P7, with the aim of dampening the initial inflammatory phase without compromising the healing and remodeling phase. Blood samples taken 9 h post-LAD surgery and P7 administration dampened the secretion of inflammatory cytokines, but this dampening effect of P7 was diminished after 3 days. Echocardiography revealed less deterioration of cardiac contraction in mice receiving P7. In line with this, less myocardial damage was observed histologically in P7-treated mice. In conclusion, the administration of a SLAMF1-derived peptide (P7) immediately after induction of MI reduces the initial myocardial inflammation, reduces infarct expansion, and leads to less deterioration of cardiac contraction.
Identifiants
pubmed: 38686379
doi: 10.3389/fimmu.2024.1383505
pmc: PMC11056545
doi:
Substances chimiques
Cytokines
0
Antigens, CD
0
Ly78 protein, mouse
0
Peptides
0
Receptors, Cell Surface
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1383505Informations de copyright
Copyright © 2024 Olsen, Kong, Louwe, Lauritzen, Schanke, Kaasbøll, Attramadal, Øgaard, Holm, Aukrust, Ryan, Espevik, Yurchenko and Halvorsen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2020 Dec 08;11:599511
pubmed: 33363540
J Cell Biol. 2018 Apr 2;217(4):1411-1429
pubmed: 29440514
Transl Res. 2016 Jan;167(1):152-66
pubmed: 26241027
Cardiovasc Res. 2005 Feb 1;65(2):469-77
pubmed: 15639486
Circ Res. 2010 Dec 10;107(12):1445-53
pubmed: 20966393
Eur Heart J. 2024 Jan 7;45(2):89-103
pubmed: 37587550
Life Sci Alliance. 2023 Oct 3;6(12):
pubmed: 37788908
Life Sci. 2004 Sep 17;75(18):2181-92
pubmed: 15325844
Cell Death Dis. 2016 May 26;7:e2234
pubmed: 27228349
Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17499-504
pubmed: 19805173
Am J Physiol Heart Circ Physiol. 2009 Jan;296(1):H1-12
pubmed: 19011041
Exp Physiol. 2013 Mar;98(3):734-45
pubmed: 23180808
Mediators Inflamm. 2018 Feb 8;2018:9874109
pubmed: 29576748
Biomed Pharmacother. 2023 Feb;158:114214
pubmed: 36916435
J Am Coll Cardiol. 2021 Apr 20;77(15):1845-1855
pubmed: 33858620
JACC Basic Transl Sci. 2020 Jul 27;5(7):735-749
pubmed: 32760860
J Cardiovasc Pharmacol. 2017 Mar;69(3):156-160
pubmed: 28267688
Front Immunol. 2021 Jul 08;12:697588
pubmed: 34305934
Cell Mol Life Sci. 2021 Feb;78(4):1233-1261
pubmed: 33057840